

# *MasterClass Series*

---

*Turn Claims Data into a  
Strategic Lever in Hard Markets*



**Kyle Wojciechowski,**  
**MSN, RN, NE-BC**

Managing Director, Cost Containment  
Benecon



**Kevin O'Brien**

Chief Business Development Officer  
Innovu

# Welcome

Thank you for investing your time in  
the Self-Funding MasterClass.

Interpreting **claims data** correctly  
gives you **control** of the narrative.

Let's **rise** to understand.

*So, you have data.  
Now what?*

*Today, we answer what data &  
how to leverage it in two ways:*

*Plan Design & Point Solutions*

# What Makes Up a **Complete** Data Set?

*Four required inputs for plan design and point solution decisions*

## **01** Claims Data

Medical and Rx claims at the line-item level — paid, allowed, service dates, diagnosis, procedure, place of service, and member identifiers.

*Enables cost, utilization, and driver analysis.*

## **02** Plan Design Data

SPD, SBC, deductibles, copays, coinsurance, OOP max, networks, exclusions, and tier structures by plan option.

*Contextualizes utilization and member behavior.*

## **03** Premiums & Funding

Equivalent rates, employer/employee contributions, enrollment by tier, fixed costs, admin fees, and funding arrangement.

*Anchors true cost and projected savings.*

## **04** Stop Loss Contract

Specific and aggregate deductibles, contract basis (12/12, 12/15, paid), lasers, reimbursement terms, and disclosure requirements.

*Defines catastrophic risk exposure.*

# Lag Risk & How Runout *Distorts* Consultant Recommendations

## % of Incurred Claims Paid by Month of Runout

30 days = 20%

90 days = 60%

365 days = 85%

## Why This Matters

- **Immature data** — paid-basis runs at 3-6 months capture only 60-85% of incurred claims.
- **Understates trend** — driving false “savings” claims and soft renewal recommendations.
- **Hides large claims** — high-dollar inpatient & specialty Rx claims lag the longest.
- **Fix:** evaluate on *incurred-with-IBNR*, require 12+ months runout before locking strategy.

# *High Prevalence* vs. *Acute* Claim Drivers Consultants Must Distinguish

MANY MEMBERS · MODERATE COST

## High Prevalence

- **Chronic & lifestyle conditions** — diabetes, hypertension, MSK, obesity, behavioral health
- **Predictable, actuarially stable** — consistent year over year
- **Point-solution addressable** — CCM, GLP-1 oversight, MSK, behavioral vendors
- **Plan-design levers** — value-based benefits, steerage, preventive incentives

*Strategy: engage & manage* with scaled vendor solutions.

FEW MEMBERS · CATASTROPHIC COST

## Acute / Catastrophic

- **High-severity events** — cancer, transplant, NICU, cell & gene therapy, trauma
- **Volatile & unpredictable** — can swing loss ratio 20+ points
- **Stop-loss driven** — SSL deductible, laser risk, disclosure integrity
- **Case-mgmt levers** — COE, specialty Rx oversight, Rx carve-out

*Strategy: protect & finance* through stop loss and clinical oversight.

# Why ICD-Level Reporting *Misleads* Renewal Strategy

*Codes alone will not put the whole story together*

## ICD CODE ALONE

### C50.911

*Malignant neoplasm, right female breast*

- ✗ Stage, grade, biomarkers
- ✗ Treatment trajectory
- ✗ Specialty Rx regimen & cost
- ✗ Site of care / unit cost
- ✗ Comorbidities & risk score
- ✗ Ongoing vs. resolved status



## WHAT RENEWAL STRATEGY ACTUALLY NEEDS

- ✓ **Episode-level roll-up** — group related claims across dates, settings, Rx
- ✓ **Risk scoring** — HCC / clinical risk adjustment on top of codes
- ✓ **Rx + medical integration** — specialty drugs often exceed the medical claim
- ✓ **Trajectory view** — ongoing, resolving, or escalating in next 12 months
- ✓ **Stop-loss alignment** — which claimants approach SSL and lasering risk
- ✓ **Actionable cohort** — who is reachable, where, and with which intervention

# Predictive Analytics: Translating Claims Insight into **Proactive Action**

*Predictions aren't guarantees — they're probabilities you can act on*

## 1. IDENTIFY

### WHAT CAN BE IDENTIFIED

- Members likely to develop a chronic condition in 12 months
- Gaps in care (labs, screenings, med adherence)
- Rising-risk members trending toward high-cost status
- Specialty Rx / therapy launches (cell & gene, GLP-1)
- Emerging stop-loss exposures

## 2. PRIORITIZE

### HOW TO PRIORITIZE

- Rank by **probability × impact**, not raw claim dollars
- Filter to members reachable by an existing benefit or vendor
- Separate **preventable** from **inevitable** cost
- Match cohort size to vendor minimums and ROI thresholds
- Validate against model confidence & backtest

## 3. ACT

### HOW TO TAKE ACTION

- Deploy targeted outreach and case/condition management
- Tune plan design: steerage, COE, site-of-care, formulary
- Disclose emerging claimants to stop-loss carrier proactively
- Re-run predictions each quarter and measure lift
- Track **avoided cost**, not just PMPM

*Use predictions to shape the next 12 months — not to promise a specific claim outcome.*

# Three Big Takeaways

1. Get access
2. Prioritize
3. Take action!

*Thank you.*



**Kyle Wojciechowski,**  
**MSN, RN, NE-BC**

Managing Director, Cost Containment  
Benecon

**Phone:** 717-874-6408

**Email:** [kwojciechowski@benecon.com](mailto:kwojciechowski@benecon.com)



**Kevin O'Brien**

Chief Business Development Officer  
Innovu

**Phone:** 412-212-7520 ext. 765

**Email:** [kobrien@innovu.com](mailto:kobrien@innovu.com)